Technical Analysis for BCYC - Bicycle Therapeutics plc

Grade Last Price % Change Price Change
C 24.12 1.52% 0.36
BCYC closed up 1.52 percent on Monday, March 18, 2024, on 1.16 times normal volume.
2 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Down

Date Alert Name Type % Chg
Pocket Pivot Bullish Swing Setup 0.00%
Golden Cross Bullish 1.52%
Pocket Pivot Bullish Swing Setup 1.52%
Inside Day Range Contraction 1.52%
Fell Below 20 DMA Bearish 5.14%
New Downtrend Bearish 5.14%
Wide Range Bar Range Expansion 5.14%
Pocket Pivot Bullish Swing Setup -5.60%
NR7 Range Contraction -5.60%
Crossed Above 20 DMA Bullish -3.67%

   Recent Intraday Alerts

Alert Time
60 Minute Opening Range Breakout about 13 hours ago
Rose Above Previous Day's High about 13 hours ago
Up 2% about 13 hours ago
Up 1% about 16 hours ago
Down 3% about 17 hours ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Bicycle Therapeutics plc Description

Bicycle Therapeutics Limited, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in preclinical studies targeting EphA2; BT8009, which is in preclinical studies targeting Nectin-4; and CD137, an immune cell co-stimulatory molecule that is in preclinical stage, as well as systemically-delivered activators. In addition, it is developing THR-149, a key immune cell co-stimulatory molecule that is in Phase I clinical trials. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, hematology, ophthalmology, and respiratory indications. The company has a clinical trial and license agreement with the Cancer Research Technology Limited and CRUK; and research collaboration agreement with Bioverativ Inc., AstraZeneca AB, and Oxurion NV. The company was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Life Sciences Disease Immunology Oncology Tumor Ophthalmology Hematology Immune Checkpoint Cancer Research Search Technology

Is BCYC a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 28.9
52 Week Low 12.54
Average Volume 322,175
200-Day Moving Average 20.61
50-Day Moving Average 20.83
20-Day Moving Average 24.62
10-Day Moving Average 24.51
Average True Range 1.48
RSI (14) 54.55
ADX 30.81
+DI 20.67
-DI 23.51
Chandelier Exit (Long, 3 ATRs) 22.79
Chandelier Exit (Short, 3 ATRs) 25.77
Upper Bollinger Bands 26.59
Lower Bollinger Band 22.66
Percent B (%b) 0.37
BandWidth 15.98
MACD Line 0.97
MACD Signal Line 1.35
MACD Histogram -0.3839
Fundamentals Value
Market Cap 909.7 Million
Num Shares 37.7 Million
EPS -4.96
Price-to-Earnings (P/E) Ratio -4.86
Price-to-Sales 26.17
Price-to-Book 1.56
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 26.21
Resistance 3 (R3) 26.07 25.23 25.86
Resistance 2 (R2) 25.23 24.70 25.30 25.74
Resistance 1 (R1) 24.68 24.37 24.96 24.82 25.63
Pivot Point 23.84 23.84 23.98 23.91 23.84
Support 1 (S1) 23.29 23.31 23.57 23.43 22.61
Support 2 (S2) 22.45 22.98 22.52 22.50
Support 3 (S3) 21.90 22.45 22.38
Support 4 (S4) 22.04